List of IQVIA Clinical Trial Payments Customers
Cambridge, CB4 0WG,
United Kingdom
Since 2010, our global team of researchers has been studying IQVIA Clinical Trial Payments customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased IQVIA Clinical Trial Payments for Payment Processing from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using IQVIA Clinical Trial Payments for Payment Processing include: Bristol Myers Squibb, a United States based Life Sciences organisation with 34100 employees and revenues of $48.30 billion, Bayer US, a United States based Oil, Gas and Chemicals organisation with 23700 employees and revenues of $12.85 billion and many others.
Contact us if you need a completed and verified list of companies using IQVIA Clinical Trial Payments, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The IQVIA Clinical Trial Payments customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Bayer US | Oil, Gas and Chemicals | 23700 | $12.9B | United States | IQVIA | IQVIA Clinical Trial Payments | Payment Processing | 2021 | n/a |
In 2021 Bayer US implemented IQVIA Clinical Trial Payments as the Payment Processing core of its Automated Site Payment Invoice Resolution ASPIREs initiative. The deployment built on a US pilot that began in 2019 and expanded into a multi-country rollout, with Bayer implementing the solution across 18 countries while internal site management teams and site administrators accessed the new payments workflows through a centralized Payments Portal.
IQVIA Clinical Trial Payments was configured to provide invoicing automation, site payment status reporting, a study-level dashboard, and a payments drill-down that surfaces banking and transaction-level detail. The solution includes a rolling monthly reconciliation capability and a reporting layer designed for real-time visibility, supporting Bayer US payments on a 28-day cycle from electronic data capture extraction to payment processing.
The implementation integrated automated data feeds from electronic data capture to drive invoice generation and payment triggers, and it leveraged IQVIA Financial Lifecycle Solutions for operational orchestration and third-party services for ancillary automation and dashboards. For a small set of countries with complex regulatory or operational requirements Bayer adopted a hybrid approach, retaining limited manual steps while applying the standardized IQVIA workflow elsewhere.
Governance and process change began with an EY-led current-state mapping exercise that identified duplicative templates, high manual handoffs, fragmented data sources, and inconsistent vendor naming. Bayer introduced standardized templates, centralized reporting, and a feedback loop with sites and internal users, including plans for a formal site satisfaction survey in 2021, to govern ongoing configuration and continuous improvement.
Stated outcomes from the ASPIREs deployment include improved site satisfaction through timelier and more transparent payments, reduced administrative burden via automation and dashboards, simplified end-of-study closeout through rolling reconciliation, and the ability to pay sites two to three times faster while reducing time spent on payment support by up to 90 percent.
|
 |
Bristol Myers Squibb | Life Sciences | 34100 | $48.3B | United States | IQVIA | IQVIA Clinical Trial Payments | Payment Processing | 2023 | n/a |
In 2023, Bristol Myers Squibb consolidated its fragmented site payments environment by transitioning from six payment systems to IQVIA Clinical Trial Payments. The deployment centralized site payment orchestration and Payment Processing across global clinical operations, unifying processes that had been segmented by geography, CRO, or acquisition into a single enterprise payments platform.
The IQVIA Clinical Trial Payments implementation standardized master service agreements and rate cards, centralized invoicing and installment scheduling, and established a single source of truth for payment tracking and exceptions management. Configuration focused on contract-driven payment terms, streamlined negotiation workflows, and operational consistency to reduce exceptions and speed contracting and site activation.
Operational coverage spanned study operations, contracts and grants, finance, and site management, supporting interactions with multiple CRO partners under a unified payments model. The Payment Processing platform improved transparency for both sponsors and sites, enabling more accurate forecasting, clearer cash flow management, and streamlined compliance and reporting across global sites.
Governance changes emphasized standardized payment terms, centralized negotiation authority for rate cards, and clearer accountability for on time installments to sites. Reported outcomes included improved sponsor-site relationships, reduced internal resource burden, increased transparency, accelerated contracting and enrollment, and greater agility to pivot across markets, all attributed to the move to IQVIA Clinical Trial Payments.
|
Buyer Intent: Companies Evaluating IQVIA Clinical Trial Payments
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||